Filing summary
Entity note: The supplied filing is for Trxade Group, Inc., not Scienture Holdings, Inc. It is a Form 10-Q for the quarter and six months ended June 30, 2016; financial statements are unaudited.
Business context and reporting period
Trxade Group operates a web-based pharmaceutical marketplace through Trxade, Inc., and sells pharmaceuticals through Westminster Pharmaceutical LLC. The filing describes a shift toward wholesale pharmaceutical sales alongside continued platform development.
Financial performance and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $1.689 million | $1.167 million | $3.536 million | $1.863 million |
| Gross profit | $649,101 | $785,191 | $1.480 million | $1.251 million |
| Gross margin | 38.4% | 67.3% | 41.9% | 67.1% |
| Operating loss | $(1.013) million | $(26,448) | $(1.323) million | $(469,099) |
| Net loss | $(1.102) million | $(54,356) | $(1.474) million | $(497,976) |
| Loss per share, basic and diluted | $(0.04) | $(0.00) | $(0.05) | $(0.02) |
For the six months ended June 30, operating cash use was $845,544, versus $696,435 in 2015. Financing provided $305,000, compared with $405,000; cash declined $540,544 to $319,588. At June 30, current assets were $1.436 million and current liabilities $1.339 million, leaving working capital of $96,105, down from $975,405 at year-end 2015. Total liabilities were $2.283 million, and shareholders’ equity was a deficit of $847,622.
Reported debt included a $250,000 promissory note, shown net of discount at $212,500; $165,000 of short-term convertible notes; and $1.2 million principal of long-term convertible notes, shown net of discount at $943,727. The long-term notes are secured. The filing does not provide a conventional interest rate for these notes; their stated payment is a royalty based on profits from certain transactions.
Changes versus prior comparable periods
- Six-month revenue rose about 90%, principally due to Westminster pharmaceutical sales. The segment table shows Westminster revenue of $2.303 million versus $508,570; Trxade revenue was $1.217 million versus $1.180 million.
- Cost of sales increased faster than revenue, reducing six-month gross margin to 41.9% from 67.1%. Management attributed this to pharmaceutical sales having higher associated costs.
- Six-month net loss widened to $1.474 million from $497,976. Management cited increased staffing and compensation, platform development, litigation costs, higher interest expense, and a $37,579 debt-extinguishment loss.
- Cash used in operations increased by $149,109 year over year. Management attributed the increase to staffing, IT development, the wholesale-sales transition, and litigation-related payments.
Outlook, risks, contingencies, and unusual items
- Management’s stated priorities for the rest of 2016 were continued platform development and customer growth. It estimated the next 12 months’ operating expenses and working-capital needs at $4.7 million: $1.2 million cost of sales and $3.5 million general and administrative expenses.
- The company said additional funds would be needed and expected to seek financing, while warning that financing may not be available on reasonable terms. Equity financing could dilute shareholders; borrowing would increase liabilities and cash commitments. No assurance was given that revenue or financing would be sufficient, and management acknowledged the company may remain unprofitable.
- A proposed $200,000 settlement resolves a “junk fax” class-action claim, subject to court approval. The company accrued $200,000 at June 30, 2016.
- In June, the company issued an additional $250,000 of secured convertible notes and warrants, extended existing secured notes to a four-year maturity, renewed a $250,000 promissory note, and sold 100,000 shares for $150,000 with accompanying warrants.
- Disclosure controls and procedures were reported as not effective at quarter-end. Management reported no material change in internal control over financial reporting during the six months.
- The filing contains inconsistent descriptions of certain expense amounts: the statements present general and administrative expense of $2.803 million for the six months, while MD&A separately identifies $2.687 million of general and administrative expense plus $116,194 of warrant and option expense.
Important facts for investors to verify
- Confirm that this Trxade Group filing is the intended filing, given the request metadata names Scienture Holdings, Inc.
- Assess near-term funding needs against $319,588 of cash, the $4.7 million estimated 12-month requirement, and limited working capital.
- Review the economics, maturity, security, conversion terms, royalty payments, and potential dilution from outstanding notes and warrants.
- Track gross margins and losses as pharmaceutical sales expand, and reconcile the expense presentation between the financial statements and MD&A.
- Check the final court approval and payment of the proposed $200,000 settlement, and monitor remediation of ineffective disclosure controls.